Thyroid Eye Disease
FDA committee unanimously recommends approval of teprotumumab for thyroid eye disease
Recent FDA actions you may have missed
Top takeaways from ATA
VIDEO: Research highlights from ATA
CHICAGO — In this video exclusive, Endocrine Today Editorial Board Member Stephanie L. Lee, MD, PhD, FACE, ECNU, professor of medicine and director of thyroid health in the section of endocrinology, diabetes and nutrition at Boston Medical Center, discusses four important studies presented at the American Thyroid Association Annual Meeting.
Researcher highlights new treatments for thyroid eye disease

CHICAGO — Thyroid eye disease, a condition most commonly associated with Graves’ hypothyroidism, typically comes with a range of symptoms that can make everyday tasks challenging and quickly reduce quality of life. Within 18 months of a diagnosis of Graves’ disease, approximately 80% of patients will develop thyroid eye disease, with symptoms including proptosis, the main cause or morbidity, as well as eyelid retraction, strabismus and compressive optic neuropathy.
Symptoms, quality of life improve with teprotumumab for adults with thyroid eye disease
CHICAGO — Among adults with recent-onset thyroid eye disease, those who received the monoclonal human antibody teprotumumab experienced substantial symptom relief and reported quality of life gains compared with those assigned placebo, according to pooled data from a phase 2 and a phase 3 clinical trial of the drug presented at the American Thyroid Association annual meeting.
Two subtypes distinguish ophthalmic Graves’ disease
SAN FRANCISCO — Rather than thinking of ophthalmic Graves’ disease as one entity classified as “mild” or “moderate to severe,” William R. Nunery, MD, FACS, told colleagues at the American Society of Ophthalmic Plastic and Reconstructive Surgery meeting that thyroid eye disease should be considered as two separate subtypes.